belinostat + pralatrexate

**Belinostat + pralatrexate** is an experimental combination therapy comprising two small-molecule anticancer drugs with distinct mechanisms of action—belinostat, a histone deacetylase inhibitor, and pralatrexate, a dihydrofolate reductase inhibitor. Both are approved individually for relapsed or refractory peripheral T-cell lymphoma (PTCL). The combination is being studied for synergistic and potentially enhanced efficacy, particularly against T-cell lymphomas, and is delivered intravenously. Clinical trials are evaluating its safety and effectiveness in newly diagnosed or previously untreated PTCL, and preclinical and early clinical evidence suggests that the combination produces additive or synergistic growth inhibitory effects on various lymphoma subtypes, including B-cell and T-cell lymphomas[2][3][5][1][9].